Immunogenicity and tolerability of hepatitis A vaccine in HIV-infected children

Clinical Infectious Diseases

Volumn 41, Issue 4, 2005, Pages 544-548

  Gouvea, A F T B ^a   De Moraes Pinto, M I ^a   Ono, E ^a   Dinelli, M I S ^a   Machado, D M ^a   Weckx, L Y ^a   Succi, Regina C M ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; HEPATITIS A ANTIBODY; HEPATITIS A VACCINE;

ANALYSIS OF VARIANCE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; BRAZIL; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEVER; HEADACHE; HEPATITIS A; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION RISK; INJECTION PAIN; LYMPHOCYTE COUNT; MYALGIA; PRIORITY JOURNAL; SEROCONVERSION; VACCINATION; VERTICAL TRANSMISSION; VIRUS LOAD; VOMITING;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HIV INFECTIONS; HUMANS; IMMUNE TOLERANCE;

EID: 23244462032     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/432055     Document Type: Article

References (17)

1. Resino S, Bellon JM, Gurbindo D, Ramos JT, Leon JA, Munoz-Fernandez MA. Responses to antiretroviral treatments in vertically HIV-1-infected children. Med Clin Barc 2002; 119:725-9.
2. Resino S, Bellon JM, Resino R, et al. Extensive implementation of highly active antiretroviral therapy shows great effect on survival and surrogate markers in vertically HIV-infected children. Clin Infect Dis 2004; 38:1605-12.
3. Meraviglia P, Schiavini M, Castagna A, et al. Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation. HIV Med 2004; 5:334-43.
4. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004; 38(Suppl 2):S90-7.
5. Scherpbier HJ, Hilhorst MI, Kuijpers TW. Liver failure in a child receiving highly active antiretroviral therapy and voriconazole. Clin Infect Dis 2003; 37:828-30.
6. Foccacia R, Conceição OJG, Sette H Jr, et al. Estimated prevalence of viral hepatitis in the general population of the municipality of São Paulo, measured by serologic survey of a stratified, randomized and residence-based population. Braz J Infect Dis 1998; 2:269-84.
7. American Academy of Pediatrics. Human immunodeficiency virus infection. In: Pickering LK, ed. Red book: 2003 report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2003:360-82.
8. Moss WJ, Clements CI, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bull WHO 2003; 81:61-70.
9. Lima M, Succi RCM, Santos AMN, Weckx LY, de Moraes-Pinto MI. Rubella immunization in human immunodeficiency virus type 1-infected children: cause for concern in vaccination strategies. Pediatr Infect Dis J 2004; 23:604-7.
10. Lange CG, Lederman MM, Medvik K, et al. Nadir CD4+ T cell count and numbers of CD28+ CD4+ T cells predicts functional responses to immunization in chronic HIV-1 infection. AIDS 2003; 17:2015-23.
11. Horng YC, Chang MH, Lee CY, Safary A, Andre FE, Chen DS. Safety and immunogenicity of hepatitis A vaccine in healthy children. Pediatr Infect Dis J 1993; 12:359-62.
12. Wang X-Y, Xu Z, Yao X, et al. Immune responses of anti-HAV in children vaccinated with live attenuated and inactivated hepatitis A vaccines. Vaccine 2004; 22:1941-5.
13. Hess G, Clemens R, Bienzle U, Schönfeld C, Schunck B, Bocck HL. Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. J Med Virol 1995; 46: 40-2.
14. Neilsen GA, Bodsworth NJ, Watts N. Response to hepatitis A vaccination in human immunodeficiency virus-infected and uninfected homosexual men. J Infect Dis 1997; 176:1064-7.
15. Kemper CA, Haubrich R, Frank I, et al. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis 2003; 187:1327-31.
16. Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: The Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003; 112:973-80.
17. Resino GS, Bellon JM, Navarro CJ, Gutierrez D, Leon LJA, Munoz-Fernandez MA. T cell subsets variation during clinical and immunological progression in vertically HIV-infected children. Medicina B Aires 2001; 61:557-65.